CD274 and non-small cell lung carcinoma: Our cohort of 118 advanced NSCLC patients treated with first-line mono-IT within routine clinical practice achieved mOS of 19.4 months and 1-year OS of 62%, not reaching those of the pivotal KEYNOTE-024 clinical trial with mOS of 26.3 months and 1-year OS of 70% but similar to those reported for patients with PD-L1 expression ≥50% in other RCTs, with mOS of approximately 20 months (9–11).